Therapeutic Applications of Cannabinoids in Cardiomyopathy and Heart Failure

Table 2

Use of cannabinoids in different cardiomyopathies.

Compound	Pharmacological activity	Cardiomyopathy model	Observed effect	Reference
SR144528	CB2 antagonist	I-R	Abolished cardioprotection of ECS, PEA, 2-AG, ACEA, and methanandamide	[50, 51, 53]
			Abolished 5-HT vasodilatory response	[52]
		Arrhythmia	No effect over ACEA protection	[58]
SR141716A (rimonabant)	CB1 antagonist	I-R	No effect over ECS and PEA cardioprotection	[50, 51]
			Abolished ACEA, methanandamide, and half 2-AG cardioprotection	[51, 53]
			Abolished 5-HT vasodilatory response	[52]
		MI	Prevention of hypotention followed by MI	[62]
		Arrhythmia	No effect over ACEA and HU.210 protection	[58, 59]
Anandamide (arachidinoylethilenamide, ACEA)	Endogenous cannabinoid, CB1 and CB2 agonist	I-R	Heart protection against ischemia	[51]
			Reduction of the infarct size	[53]
		Arrhythmia	Increase resistance to arrhythmogenic effects of epinephrine	[58]
			Improvement on cardiac resistance to arrhythmia	[60]
		Pulmonary artery hypertension	Endothelium-dependent pulmonary artery relaxation	[70]
2-arachidonoylglycerol (2-AG)	Endogenous cannabinoid, CB1 and CB2 agonist	I-R	Heart function recovery after reperfusion	[51]
			Protection of preconditioning on the endothelial function	[52]
Palmitoylethanolamide (PEA)	Endogenous cannabinoid, CB1 agonist	I-R	Heart function recovery after reperfusion	[51]
			Protection of preconditioning on the endothelial function	[52]
			No effect on infarct reduction	[53]
JWH105	CB2 agonist	I-R	Heart protection against ischemia	[51]
Methanandamide	Non-hydrolyzable anandamide analog	I-R	Reduction of the infarct size	[53]
		Arrhythmia	Improvement on cardiac resistance to arrhythmia	[60]
JWH-133	CB2 agonist	I-R	No effect on infarct reduction	[53]
			Reduction of myocardial injury	[56]
WIN55212-2	CB2 ligand	I-R	Protection against myocardial damage	[55]
AM630	CB2 antagonist	I-R	Abolished cardioprotection of WIN55212-2 and JWH-133	[55, 56]
AM251	CB1 antagonist	I-R	No effect on WIN55212-2 cardioprotection	[55]
HU-210	CB1 and CB2 agonist	I-R	Cardioprotection by mimic postconditioning	[57]
		Arrhythmia	Antiarrhythmic effects	[59]
Abnormal cannabidiol	Regioisomer of CBD	Diabetic cardiomyopathy	Hemodynamic, reduction of LV contractility and relaxation index	[63, 64]